Cell transplantation therapy with ILK-modified cardiac progenitor cells (CPCs) and mesenchymal stem cells (MSCs) has been demonstrated to promote post-infarction angiogenesis, reduce fibrosis and apoptosis, thereby preserving left ventricular function and myocardial perfusion and shrinking infarct size (41, 53). The gene discussed is ILK; the disease is infarction.